Tarsus Pharmaceuticals CEO and board chair Bobak Azamian sold 10,000 shares across two transactions at $90.27 to $91.27 per share. The transactions leave Azamian with 827,991 shares, giving investors the reported post-sale ownership position of the company’s president, CEO and board chair.
Key Highlights
- The transactions occurred on 4 September 2026.
- Both transactions used SEC transaction code S, indicating open-market sales.
- Bobak Azamian owned 827,991 shares after the transactions.
The sale was completed through two transactions. The transactions took place on 4 September 2026. Both entries carried SEC transaction code S, which identifies an open-market sale. Code S distinguishes the entries as sales rather than awards, purchases, tax-related withholding, option exercises or gifts.
Post-Transaction Ownership
Azamian owned 827,991 shares after the transactions. The reported balance represents his ownership position following the two sales. The ownership figure gives investors the stated post-transaction share balance for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)’s senior executive and board leader.
FAQs
Q: How many Tarsus Pharmaceuticals shares did Bobak Azamian sell?
A: Bobak Azamian sold 10,000 Tarsus Pharmaceuticals shares. The transactions were completed at prices ranging from $90.27 to $91.27 per share.
Q: When did the Tarsus Pharmaceuticals insider sale occur?
A: The Tarsus Pharmaceuticals insider sale occurred on 4 September 2026. It covered two separate transactions, and both used SEC transaction code S.
Q: How many Tarsus Pharmaceuticals shares does Azamian own after the sale?
A: Bobak Azamian owned 827,991 Tarsus Pharmaceuticals shares after the two transactions completed on 4 September 2026. This reported balance represents his post-transaction ownership position in Tarsus Pharmaceuticals, Inc. (NASDA
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.